Learning from the "tsunami" of immune checkpoint inhibitors in 2015

Critical Reviews in Oncology/Hematology

Volumn 101, Issue , 2016, Pages 213-220

  Kourie, Hampig Raphael ^a   Awada, Gil ^b   Awada, Ahmad Hussein ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

2015; Cancer; Immune checkpoint inhibitors; Round up; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; CARBOPLATIN; DACARBAZINE; DOCETAXEL; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN ANTIBODY; RECEPTOR ANTIBODY; TICILIMUMAB; UNCLASSIFIED DRUG;

ANUS CANCER; BILIARY TRACT CANCER; CUTANEOUS MELANOMA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MERKEL CELL TUMOR; METASTATIC MELANOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PUBLICATION; REVIEW; SIDE EFFECT; SMALL CELL LUNG CANCER; TRANSITIONAL CELL CARCINOMA; COST OF ILLNESS; ECONOMICS; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

COMBINED MODALITY THERAPY; COST OF ILLNESS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84961878101     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.03.017     Document Type: Review

References (45)

1. Abiko K., Matsumura N., Hamanishi J., et al. IFN-(from lymphocytes induces PD-l1 expression and promotes progression of ovarian cancer. Br. J. Cancer 2015, 112(9):1501-1509. (Apr 28).
2. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372(4):311-319. (Jan 22).
3. Antonia S.J., Bendell J.C., Taylor M.H., et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J. Clin. Oncol. 2015, 33. (suppl; abstr 7503).
4. Antonia S.J., Goldberg S.B., Balmanoukian A.N., et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-l1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J. Clin. Oncol. 2015, 33. (suppl; abstr 3014).
5. Bang Y.J., Doi T., De Braud F., et al., Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028. ECC, 2015, abstract 525.
6. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373(17):1627-1639. (Oct 22).
7. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015, 373(2):123-135. (Jul 9).
8. Burton A.L., Roach B.A., Mays M.P., et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am. Surg. 2011, 77:188-192.
9. Disis M.L., Patel M.R., Pant S., et al. Avelumab (MSB0010718C), an anti-pD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J. Clin. Oncol. 2015, 33. (suppl; abstr 5509).
10. Eggermont A.M., Chiarion-Sileni V., Grob J.J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015, 16(May (5)):522-530.
11. El-Khoueiry A., Melero I., Crocenz T., et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol. 2015, 33. (suppl; abstr LBA101).
12. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372(21):2018-2028. (May 21).
13. Gelao L., Criscitiello C., Esposito A., et al. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an innocent bystander. Toxins (Basel) 2014, 6(3):914-933. (Mar 3).
14. Gulley J.L., Spigel D., Kelly K., et al. Avelumab (MSB0010718C), an anti-pD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol. 2015, 33. (suppl; abstr 8034).
15. Hamanishi J., Mandai M., Ikeda T., et al. Safety and antitumor activity of anti-pD-1 antibody nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 2015, 33(34):4015-4022. (Dec 1).
16. Hematology and oncology (cancer) approvals and safety notifications US Food and Drug Administration (FDA) 2016, (website). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm.
17. Hodi F., Gibney G., Sullivan R., et al. An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). ECC, 2015, Abstract 23 LBA.
18. Hoos A., Eggermont A.M., Janetzki S., et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102:1388-1397.
19. Hsu C., Lee S., Ejadi S., et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. ECC, 2015, abstract 2801.
20. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373(1):23-34. (Jul 2).
21. Le D.T., Uram J.N., Wang H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372(26):2509-2520. (Jun 25).
22. Liu S., Powderly J., Camidge D., et al. Safety and efficacy of MPDL3280A (anti-pDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2015, 33. (suppl; abstr 8030).
23. Loi S., Sirtaine N., Piette F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: bIG 02-98. J. Clin. Oncol. 2013, 31(7):860-867.
24. Motzer R.J., Rini B.I., McDermott D.F., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 2015, 33(13):1430-1437. (May 1).
25. Motzer R.J., Escudier B., McDermott D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015, 373(19):1803-1813. (Nov 5).
26. Nghiem P., Bhatia S., Daud A., et al. LATE BREAKING ABSTRACT: Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. ECC, 2015, abstract 22LBA.
27. Ott P.A., Piha-Paul S.A., Munster P., et al. Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. ECC, 2015, abstract 500.
28. Ott P.A., Fernandez M.E., Hiret S., et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J. Clin. Oncol. 2015, 33. (suppl; abstr 7502).
29. Patnaik A., Mark Socinski A., Matthew Gubens A., et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J. Clin. Oncol. 2015, 33. (suppl; abstr 8011).
30. Plimack E., Bellmunt J., Gupta S., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol. 2015, 33. (suppl; abstr 4502).
31. Postow M.A., Chesney J., Pavlick A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372(21):2006-2017. (2015 May).
32. Reardon D., Gokhale P., Hodi F., et al. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. J. Clin. Oncol. 2016, 32(5s). (suppl; abstr 2084).
33. Ribas A., Puzanov I., Dummer R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015, 16(August (8)):908-918.
34. Rizvi N.A., Hellmann M.D., Snyder A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
35. Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372(4):320-330. (Jan 22).
36. Robert C., Schachter J., Long G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372(26):2521-2532. (Jun 25).
37. Rosenberg J., Petrylak D., Abidoye O., et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). ECC, 2015, abstract 21LBA.
38. Segal N.H., Ignatius S.H., Balmanoukian A.S., et al. Safety and efficacy of MEDI4736, an anti-pD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J. Clin. Oncol. 2015, 33. (suppl; abstr 3011).
39. Seiwert T., Weiss B., et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-hPV-associated head and neck (H/N) cancer. J. Clin. Oncol. 2014, 32:5s. (suppl; abstr 6011).
40. Seiwert T., Haddad R., Gupta S., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. J. Clin. Oncol. 2015, 33:A6008. (suppl; abstr LBA6008).
41. Snyder A., Makarov V., Merghoub T., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
42. Vansteenkiste J., Fehrenbacher L., Spira A.I., et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer. Primary Analyses for Efficacy, Safety and Predictive Biomarkers from a Randomized Phase II Study (POPLAR) 2015, Abstract 14 LBA.
43. Varga A., Piha-Paul S.A., Ott P.A., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-l1 positive advanced ovarian cancer: interim results from a phase Ib study. J. Clin. Oncol. 2015, 33. (suppl; abstr 5510).
44. Weber J.S., O'Day S., Urba W., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 2008, 26(36):5950-5956. (Dec 20).
45. Weber J.S., D'Angelo S.P., Minor D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-cTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015, 16(April (4)):375-384.